Valuation: Pharmaniaga

Market Cap 1B 247M 221M 204M 185M 345M 23.48B 351M 2.43B 975M 12.35B 928M 908M 38.94B P/E 2026 *
12.6x
P/E 2027 * 11.2x
Enterprise Value 1B 247M 221M 204M 185M 345M 23.48B 351M 2.43B 975M 12.35B 928M 908M 38.94B EV / Sales 2026 *
0.24x
EV / Sales 2027 * 0.24x
Free-Float
37.97%
Yield 2026 *
19.9%
Yield 2027 * 26.8%
08-13 Pharmaniaga Berhad Announces Appointment of Mohd Firdaus Bin Zulkifli as Non Independent and Non Executive Member of Audit Committee, Effective August 17, 2026 CI
08-13 Pharmaniaga Berhad Announces Appointment of Mohd Firdaus Bin Zulkifli as A Member of Nomination and Remuneration Committee, Effective August 17, 2026 CI
08-13 Pharmaniaga Berhad Announces second Interim Dividend for the Financial Year Ended 31 December 2026, Payable on 13 October 2026 CI
08-13 Pharmaniaga Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-17 Pharmaniaga Berhad Announces Redesignation of Dato' Dr Faridah Aryani Binti Md Yusof from Member of Risk Committee to Independent and Non Executive Chairman of Risk Committee, Effective 16 July 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Dato Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Director, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Redesignation of Encik Mohd Firdaus Bin Zulkifli as Non Independent and Non Executive Director from Alternate Director, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Dato' Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Member of Audit Committee, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Mohd Zahir Bin Zahur Hussain as Chairman of the Risk Committee, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Mohd Zahir Bin Zahur Hussain as Member of the Nomination and Remuneration Committee, Effective July 1, 2026 CI
06-10 Pharmaniaga Completes 5:1 Share Consolidation MT
05-28 Pharmaniaga says government of Malaysia accepts unit's tender to supply insulin for 3 years RE
05-18 Pharmaniaga Berhad Announces First Interim Dividend for the Financial Year Ended 31 December 2026, Payable on 03 July 2026 CI
1 day-3.16%
1 week-4.97%
1 month-26.44%
3 months-35.17%
6 months-37.55%
Current year-46.32%
1 week 0.76
Extreme 0.765
0.81
1 month 0.76
Extreme 0.765
1.03
Current year 0.76
Extreme 0.765
1.7
1 year 0.76
Extreme 0.765
1.7
3 years 0.65
Extreme 0.65
2.35
5 years 0.65
Extreme 0.65
4.4
10 years 0.65
Extreme 0.65
7.25
Manager TitleAgeSince
Chief Executive Officer 54 31/08/2024
Director of Finance/CFO 59 31/05/2012
Chief Administrative Officer 53 30/09/2024
Director TitleAgeSince
Director/Board Member 55 19/11/2020
Director/Board Member 54 29/02/2024
Director/Board Member 51 19/08/2021
Date Insider Type Main position Quantity % Market Cap. Importance
27/03/26 Buy

Director

300,000 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
-3.16%-4.97%-37.55%-62.22% 247M
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.56%+4.81%+38.17%+69.88% 426.22B
Weighted average by Cap. +2.01%+6.60%+50.50%+100.43%

Financials

2026 *2027 *
Net sales 4.13B 1.02B 912M 839M 760M 1.42B 96.72B 1.45B 10.01B 4.02B 50.88B 3.82B 3.74B 160B 4.26B 1.05B 941M 865M 784M 1.47B 99.72B 1.49B 10.32B 4.14B 52.46B 3.94B 3.86B 165B
Net income 93.3M 22.99M 20.59M 18.94M 17.16M 32.08M 2.18B 32.68M 226M 90.68M 1.15B 86.29M 84.46M 3.62B 113M 27.84M 24.93M 22.94M 20.78M 38.85M 2.64B 39.57M 274M 110M 1.39B 104M 102M 4.39B
Net Debt - -
Projected Income Statement - Annual - Pharmaniaga
Logo Pharmaniaga
Pharmaniaga Berhad is an investment holding company engaged in the provision of management services to its subsidiaries. The Company’s segments include Manufacturing, Logistics and distribution, and Indonesia. The Manufacturing segment is engaged in manufacturing of pharmaceutical products in Malaysia. The Logistics and distribution segment includes distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia. The Indonesia segment is engaged in manufacturing and distribution of pharmaceutical and medical products in Indonesia. Its product portfolio comprises oral solid dosages, liquid, cream and small volume injectables. It also manufactures general pharmaceuticals, including penicillin, cephalosporin and over-the-counter products. Its research and development capabilities include drug formulation and analytical development, process scale-up, clinical research and product localization.
Employees
3,502
Date Price Change Volume
30/10/26 MYR 0.7650 -3.16% 2,431,400
29/10/26 MYR 0.7900 +1.94% 1,184,800
28/10/26 MYR 0.7750 -1.90% 2,045,500
27/10/26 MYR 0.7900 -0.63% 448,300
26/10/26 MYR 0.7950 -1.24% 448,200
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Pharmaniaga
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.7650MYR
Average target price
1.530MYR
Spread / Average Target
+100.00%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Pharmaniaga
  1. Stock Market
  2. Stocks
  3. 7081 Stock